HC Wainwright & Co. has initiated coverage on Cormedix (CRMD, Financial) with a 'Buy' rating, according to analyst Brandon Folkes. The announcement was made on June 30, 2025, marking a significant development for Cormedix as it continues to navigate the market landscape.
The analyst has set a price target of $20.00 USD for CRMD. This target reflects the firm's optimistic outlook on the stock's potential performance in the coming periods.
This new coverage by HC Wainwright & Co. constitutes a notable event, as no prior analyst ratings or price targets were set for CRMD. The 'Buy' rating suggests confidence in the company's growth prospects and potential value creation for investors.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Cormedix Inc (CRMD, Financial) is $18.83 with a high estimate of $22.00 and a low estimate of $15.00. The average target implies an upside of 50.67% from the current price of $12.50. More detailed estimate data can be found on the Cormedix Inc (CRMD) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Cormedix Inc's (CRMD, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
